Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-4621 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral (MK-4621), Intravenous (pembrolizumab)
01
Overview
MK-4621 + pembrolizumab is an investigational combination therapy comprised of MK-4621, a double-stranded 5'-triphosphate RNA oligonucleotide agonist of retinoic acid-inducible gene I (RIG-I), and pembrolizumab, a monoclonal antibody targeting programmed cell death 1 (PD-1). MK-4621 activates the RIG-I pathway, inducing type I interferon signaling and innate immune activation, with direct tumor cell death preferentially in malignant cells. Pembrolizumab inhibits the interaction of PD-1 on immune cells with PD-L1/PD-L2 on tumor cells, preventing immune exhaustion and enhancing antitumor immune responses. The combination is developed as an immunotherapy approach for advanced or metastatic solid tumors with the hypothesis that RIG-I agonism could augment checkpoint blockade efficacy by promoting a stronger immune response within tumors[1][3][4][6].
- Other names
- MK-4621 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MK-4621 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-4621 + pembrolizumab.